| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/23/2004 | US20040186058 Peptide is chemically linked to the carrier moiety through a non-therapeutic linker species; to enhance the absorption and bioavailability of an active peptide drug substance |
| 09/23/2004 | US20040186057 Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use |
| 09/23/2004 | US20040186055 PsiepsilonRACK peptide composition and method for protection against tissue damage due to ischemia |
| 09/23/2004 | US20040186054 Angiopoietin and fragments, mutants, and analogs thereof and uses of the same |
| 09/23/2004 | US20040186053 Having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of Leu Ala Pro Ser Pro Gln Ser Pro Glu Thr 1 5 10 Pro Ala [SEQ ID NO:16], and producing rapid inhibition of factor Xa in the presence of protein Z, calcium ions and cephalin. |
| 09/23/2004 | US20040186052 Administering to a patient suffering from neurological disorder a therapeutically effective amount of an RDP-58 peptide |
| 09/23/2004 | US20040186051 Apo-2 ligand variants and uses thereof |
| 09/23/2004 | US20040186050 Method for orally administering parathyroid hormone (pth) |
| 09/23/2004 | US20040186049 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 09/23/2004 | US20040186048 Gene regulation therapy involving ferritin |
| 09/23/2004 | US20040186047 Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing |
| 09/23/2004 | US20040186045 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/23/2004 | US20040185559 Modulation of diacylglycerol acyltransferase 1 expression |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185533 Corticotropin-releasing factor2 receptors |
| 09/23/2004 | US20040185529 Isomerases proteins |
| 09/23/2004 | US20040185527 Isolated human transporter proteins nucleic acid molecules encoding human transporter proteins and uses thereof |
| 09/23/2004 | US20040185520 Compounds and methods for detecting tripeptidyl protease I |
| 09/23/2004 | US20040185510 Administering a composition sufficient for external imaging, a peptide of given formula; radioactive scanning or by magnetic resonance; use for detecting metastasis; kits |
| 09/23/2004 | US20040185508 Methods and reagents for modulating cholesterol levels |
| 09/23/2004 | US20040185507 Isolated monoclonal antibody comprising a light and heavy chain variable of given sequence; diagnosing, treating and preventing prostate/colon cancer and renal carcinoma |
| 09/23/2004 | US20040185503 Administering peroxisome proliferator-activated receptor agonist; assaying substance for up-regulating the expression of fatty acid-binding protein; glomerulonephritis, nephrotic syndrome, focal glomerulosclerosis |
| 09/23/2004 | US20040185468 Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
| 09/23/2004 | US20040185460 kits for drug screening by gel-shift assay, western blot, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two hybrid analysis, and enzyme linked immunosorbent assay (ELISA) |
| 09/23/2004 | US20040185450 Comprises nucleotide sequences coding macrophage chemoattractant protein-1 for prevention and treatment of psychological and cell proliferative disorders |
| 09/23/2004 | US20040185442 Novel polypeptide-human retinoic acid-responsive protein 53.57 and a polynucleotide encoding the same |
| 09/23/2004 | US20040185440 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin; for drug screening |
| 09/23/2004 | US20040185433 such as acyclovir/valaciclovir or penciclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention |
| 09/23/2004 | US20040185428 Lectin protein prepared from korean marine crab philyra pisum, process for preparing the same and the use thereof |
| 09/23/2004 | US20040185125 Daily administering a mixture of zinc salt, cyclo-Hispro (soybean protein product), arachidonic acid; treating hypertension, high cholesterol, weight control; nutritional supplements, foods |
| 09/23/2004 | US20040185113 Sparingly water-soluble calcium-containing inorganic microparticles and a drug or biodrug encapsulated therein; made by adding a calcium compound to a solution of a carbonate, phosphate, oxalate or urate and the drug to form the calcium salt of the carbonate, phosphate, oxalate or urate |
| 09/23/2004 | US20040185104 Biodegradable and water soluble polyesterether block polymers possessing reverse thermal gelation properties, used for drug delivery of genes, peptides, anticancer or antiproliferative agents |
| 09/23/2004 | US20040185103 Methods and compositions for enhanced delivery of bioactive molecules |
| 09/23/2004 | US20040185083 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| 09/23/2004 | US20040185060 Immunological enhancement agent comprising N-terminal peptide of p43 as an effective component |
| 09/23/2004 | US20040185059 Biotin-binding receptor molecules |
| 09/23/2004 | US20040185049 Administering to animal an interleukin-27R/cytokine receptor (IL-27R/WSX-1) ligand to treat autoimmune diseases; antiasthmatics, antiallergens, and antiinflammatory agents; diabetes |
| 09/23/2004 | US20040185048 Modulation of IL-2- and IL-15-mediated T cell responses |
| 09/23/2004 | US20040185046 Methods of treating autoimmune disease via CTLA-4Ig |
| 09/23/2004 | US20040185038 loss of immunogenicity is achieved by amino acid substitution, addition or deletion, conducted at a position which in the non-modified polypeptide remains uncleaved by a protease of the MHC class II proteolytic pathway |
| 09/23/2004 | US20040185036 treatment of platelets with certain sugar molecules, which is believed to lead to glycation of the exposed beta G1cNAc residues on GP1b alpha reduced platelet clearance, phagocytosis, increased circulation time, and increased platelet storage time |
| 09/23/2004 | US20040185035 Dietary supplements and methods for treating pain and inflammation |
| 09/23/2004 | US20040185033 Tumor antigens and CTL clones isolated by a novel procedure |
| 09/23/2004 | US20040185030 Methods and materials for treating inflammatory diseases |
| 09/23/2004 | US20040182383 Method for treating diabetes mellitus in a patient |
| 09/23/2004 | DE29724845U1 Use of troponin subunits as angiogenesis inhibitors - used for treating e.g. tumours, ocular neovascularisation, arthritis, psoriasis, atherosclerotic plaques or nonunion fractures |
| 09/23/2004 | DE202004009305U1 Dietetic oral supplement, e.g. capsule or tablet, for people with physiological deficiency symptoms, especially undergoing statin therapy, contains coenzyme Q10 plus other substance(s) assisting cellular energy recovery |
| 09/23/2004 | DE10308885A1 Using solutions of glycosidase for treating diseases associated with neuronal injury e.g. Alzheimer's or Parkinson's diseases, act by improving contact between neurons and other cells or surfaces |
| 09/23/2004 | CA2557737A1 Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications |
| 09/23/2004 | CA2523776A1 Baff mutants with at least one amino acid substitution and methods of their production |
| 09/23/2004 | CA2522818A1 Pharmaceutical preparations comprising acid-stabilised insulin |
| 09/23/2004 | CA2518912A1 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 09/23/2004 | CA2518905A1 Extraction and use of collagen extracted from either a sea mammal or a bony fish |
| 09/23/2004 | CA2518898A1 Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
| 09/23/2004 | CA2518782A1 Oligonucleotide mimetics |
| 09/23/2004 | CA2518763A1 Treatment and/or prevention of non-viral epithelial damage |
| 09/23/2004 | CA2518549A1 Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies |
| 09/23/2004 | CA2518541A1 Gonadal function improving agents |
| 09/23/2004 | CA2518407A1 Animal model simulating neurologic disease |
| 09/23/2004 | CA2518406A1 Thiol-mediated drug attachment to targeting peptides |
| 09/23/2004 | CA2518383A1 Il-2 transmembrane constructs |
| 09/23/2004 | CA2518357A1 Method of treating cancer with azaspirane compositions |
| 09/23/2004 | CA2518262A1 Uses of il-23 agonists and antagonists; related reagents |
| 09/23/2004 | CA2518216A1 Oral insulin therapies and protocol |
| 09/23/2004 | CA2517160A1 Method of treating and preventing hyperparathyroidism with vitamin d compounds |
| 09/23/2004 | CA2516572A1 Improved antitumoral treatments |
| 09/23/2004 | CA2515288A1 Compositions with hematopoietic and immune activity |
| 09/23/2004 | CA2514981A1 Use of recombinant albumin in dialysis after liver failure |
| 09/23/2004 | CA2500521A1 Novel nucleic acids and polypeptides |
| 09/22/2004 | EP1460134A1 SUGAR TRANSFERASE GnT-V HAVING ANGIOGENIC EFFECT |
| 09/22/2004 | EP1460132A1 Antibodies with specific immunoreactivity to thyroid carcinoma cells |
| 09/22/2004 | EP1460087A1 Methods of treating vascular disease with TNF antagonists |
| 09/22/2004 | EP1460084A1 Novel peptide sy |
| 09/22/2004 | EP1459768A2 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 09/22/2004 | EP1459764A1 Remedies for mild recognition deflict |
| 09/22/2004 | EP1459763A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug |
| 09/22/2004 | EP1459762A1 Preventives remedies for proliferative organ diseases chronic arthritic diseases hypertrophic scar or keloid |
| 09/22/2004 | EP1459759A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
| 09/22/2004 | EP1459758A1 Agents promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells |
| 09/22/2004 | EP1459757A1 Immunomodulating polymers |
| 09/22/2004 | EP1459756A1 REMOVAL PROMOTERS AND INHIBITOR FOR APOPTOSIS CELLS i IN VIVO /i |
| 09/22/2004 | EP1459755A1 Body weight gain inhibitor |
| 09/22/2004 | EP1459738A1 Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties |
| 09/22/2004 | EP1459070A2 Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers |
| 09/22/2004 | EP1459065A2 Processes for the measurement of the potency of glatiramer acetate |
| 09/22/2004 | EP1458883A2 Screening method for agents useful in treating diabetes |
| 09/22/2004 | EP1458870A1 COMPOSITIONS AND PROCESSES USING siRNA, AMPHIPATHIC COMPOUNDS AND POLYCATIONS |
| 09/22/2004 | EP1458866A2 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 09/22/2004 | EP1458865A2 Human vanilloid receptor protein and polynucleotide sequence encoding same |
| 09/22/2004 | EP1458864A1 Tgf-beta-specific covalently closed antisense molecule |
| 09/22/2004 | EP1458863A1 A system for stable expression of sirnas in mammalian cells |
| 09/22/2004 | EP1458862A2 Suppression of polymeric alleles |
| 09/22/2004 | EP1458861A2 Ides, an igg-degrading enzyme of streptococcus pyogenes |
| 09/22/2004 | EP1458858A2 Histone h3 methyltransferase polypeptide |
| 09/22/2004 | EP1458848A2 Nucleic acid nematicides |
| 09/22/2004 | EP1458847A1 Novel nucleic acids, polypeptides, methods of making, and uses thereof |
| 09/22/2004 | EP1458758A2 Adiponectin fragments and conjugates |
| 09/22/2004 | EP1458757A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 09/22/2004 | EP1458756A1 Chemokine mutants acting as chemokine antagonists |
| 09/22/2004 | EP1458755A2 Novel g-protein coupled receptors and dna sequences thereof |